Il dossier Eli Lilly-Abivax scalda i titoli del pharma, ma per il big italiano della diagnostica molecolare serve qualche segnale in più
🇮🇹 #italia #finanza #notizie #mercati #borsa #investire #portafoglio
🇮🇹 #italia #finanza #notizie #mercati #borsa #investire #portafoglio
Diasorin in forza con il pharma, ecco cosa succede all'azione
Il dossier Eli Lilly-Abivax scalda i titoli del pharma, ma per il big italiano della diagnostica molecolare serve qualche segnale in più
www.ftaonline.com
January 13, 2026 at 11:40 AM
Il dossier Eli Lilly-Abivax scalda i titoli del pharma, ma per il big italiano della diagnostica molecolare serve qualche segnale in più
🇮🇹 #italia #finanza #notizie #mercati #borsa #investire #portafoglio
🇮🇹 #italia #finanza #notizie #mercati #borsa #investire #portafoglio
France denies contact with Eli Lilly over reported $17.5 bln Abivax deal
France denies contact with Eli Lilly over reported $17.5 bln Abivax deal
France's Finance Ministry said on Monday it had received no formal request for investment approval regarding French biotech Abivax and had no contact with U.S. pharmaceutical giant Eli Lilly, contradicting a media report that Eli Lilly was preparing a 15 billion euro ($17.5 billion) bid for the company.
reut.rs
January 12, 2026 at 9:40 PM
France denies contact with Eli Lilly over reported $17.5 bln Abivax deal
💊Eli Lilly is prepared to offer about €15B to acquire French biotech Abivax, La Lettre reported. The newspaper said Lilly is awaiting guidance from France’s Ministry of Economy on whether the deal would be subject to foreign investment controls. Details: en.oninvest.com/article/fren...
French biotech Abivax jumps 20% on news of possible takeover by Eli Lilly – Oninvest
Eli Lilly could reportedly pay twice the market price for Abivax; six months ago, Abivax shares jumped sixfold in a day on news of successful trials of its lead drug
en.oninvest.com
January 12, 2026 at 8:35 PM
💊Eli Lilly is prepared to offer about €15B to acquire French biotech Abivax, La Lettre reported. The newspaper said Lilly is awaiting guidance from France’s Ministry of Economy on whether the deal would be subject to foreign investment controls. Details: en.oninvest.com/article/fren...
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
January 12, 2026 at 5:05 PM
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
$ABVX +4.5% [Abivax shares surge on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.] notreload.xyz/eli-lilly-ey...
Eli Lilly Eyes €15B Abivax Buyout for Colitis Drug Success
Abivax shares surge 4% on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.
notreload.xyz
January 12, 2026 at 3:58 PM
$ABVX +4.5% [Abivax shares surge on reports of Eli Lilly's €15B buyout interest. The French biotech's experimental ulcerative colitis drug obefazimod attracts big pharma attention after trial success.] notreload.xyz/eli-lilly-ey...
📊 🎯 $LLY-$ABVX M&A tape: La Lettre says Lilly is prepared to go up to €15B ($17.5B), with a $190–195 bid range in circulation—vs ~$7.8B $ABVX mkt cap, setting up a binary spread on “no formal bid yet” risk.
Deal chatter lands alongside a risk-on backdrop and a broader pharma land-grab: ~$40B of
Deal chatter lands alongside a risk-on backdrop and a broader pharma land-grab: ~$40B of
January 12, 2026 at 3:22 PM
📊 🎯 $LLY-$ABVX M&A tape: La Lettre says Lilly is prepared to go up to €15B ($17.5B), with a $190–195 bid range in circulation—vs ~$7.8B $ABVX mkt cap, setting up a binary spread on “no formal bid yet” risk.
Deal chatter lands alongside a risk-on backdrop and a broader pharma land-grab: ~$40B of
Deal chatter lands alongside a risk-on backdrop and a broader pharma land-grab: ~$40B of
La France n'a pas reçu de demande d'autorisation d'investissement avec Eli Lilly dans la société de biotechnologie Abivax
www.bloomberg.com/news/article...
www.bloomberg.com/news/article...
French Government Says No Contact With Eli Lilly on Abivax
France’s finance ministry said Monday that it has not been contacted regarding a possible bid from Eli Lilly & Co. to buy biotech company Abivax SA, as would be mandatory under the country’s inves...
www.bloomberg.com
January 12, 2026 at 3:21 PM
La France n'a pas reçu de demande d'autorisation d'investissement avec Eli Lilly dans la société de biotechnologie Abivax
www.bloomberg.com/news/article...
www.bloomberg.com/news/article...
Lilly has yet to submit a formal bid and is awaiting a regulatory green light, the outlet reported.
https://sherwood.news/markets/abivax-rises-amid-report-eli-lilly-is-preparing-a-eur15-billion-bid/
https://sherwood.news/markets/abivax-rises-amid-report-eli-lilly-is-preparing-a-eur15-billion-bid/
Abivax rises amid report Eli Lilly is preparing a €15 billion bid
Lilly has yet to submit a formal bid and is awaiting a regulatory green light, the outlet reported....
sherwood.news
January 12, 2026 at 3:09 PM
Lilly has yet to submit a formal bid and is awaiting a regulatory green light, the outlet reported.
https://sherwood.news/markets/abivax-rises-amid-report-eli-lilly-is-preparing-a-eur15-billion-bid/
https://sherwood.news/markets/abivax-rises-amid-report-eli-lilly-is-preparing-a-eur15-billion-bid/
JUST IN: FRENCH FINANCE MINISTRY HAS RECEIVED NO REQUEST SEEKING INVESTMENT APPROVAL IN PHARMA CO ABIVAX, OFFICIAL SAYS, AS PER REUTERS
X
X
January 12, 2026 at 2:38 PM
JUST IN: FRENCH FINANCE MINISTRY HAS RECEIVED NO REQUEST SEEKING INVESTMENT APPROVAL IN PHARMA CO ABIVAX, OFFICIAL SAYS, AS PER REUTERS
X
X
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a ‘sledgehammer’ to innovation, longevity medicine, and much more news.. statnews.com/pharmalot/20... #pharma #biotech #weight #obesity #Abivax #NovoNordisk #EliLilly #Amazon
Pharmalittle: We're reading about a 'sledgehammer' to innovation, longevity medicine, and more
Noubar Afeyan, one of biotech’s top investors, warned that a backlash against science in the U.S. could take “a sledgehammer” to biotech innovation
statnews.com
January 12, 2026 at 2:13 PM
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a ‘sledgehammer’ to innovation, longevity medicine, and much more news.. statnews.com/pharmalot/20... #pharma #biotech #weight #obesity #Abivax #NovoNordisk #EliLilly #Amazon
European markets begin the week lower; Abivax soars 30% amid takeover speculation
January 12, 2026 at 1:30 PM
European markets begin the week lower; Abivax soars 30% amid takeover speculation
Shares in #Abivax were tracking up this morning as a media report in #France suggested a #takeover by #EliLilly – worth €15 billion ($17.5 billion) – could be on the cards.
pharmaphorum.com/news/abivax-...
pharmaphorum.com/news/abivax-...
Abivax climbs on Lilly takeover speculation
Shares in Abivax were tracking up this morning as a media report in France suggested it could see a €15bn takeover offer from Eli Lilly.
pharmaphorum.com
January 12, 2026 at 1:17 PM
Shares in #Abivax were tracking up this morning as a media report in #France suggested a #takeover by #EliLilly – worth €15 billion ($17.5 billion) – could be on the cards.
pharmaphorum.com/news/abivax-...
pharmaphorum.com/news/abivax-...
Spéculations boursières : informations non confirmées d'une future OPA sur Abivax, le cours s'envole ce jour de plus de +27%: Après un rallye boursier de plus de plus de +1.292% en 2025, la spéculation boursière sur le titre Abivax ne fléchit pas en 2026. Rumeurs d'OPA récurrentes.
Spéculations boursières : informations non confirmées d'une future OPA sur Abivax, le cours s'envole ce jour de plus de +27%
Après un rallye boursier de plus de plus de +1.292% en 2025, la spéculation boursière sur le titre Abivax ne fléchit pas en 2026. Rumeurs d'OPA récurrentes.
dlvr.it
January 12, 2026 at 1:15 PM
Spéculations boursières : informations non confirmées d'une future OPA sur Abivax, le cours s'envole ce jour de plus de +27%: Après un rallye boursier de plus de plus de +1.292% en 2025, la spéculation boursière sur le titre Abivax ne fléchit pas en 2026. Rumeurs d'OPA récurrentes.
Lilly reportedly ready with €15B bid for Abivax firstwordpharma.com/story/7058047
January 12, 2026 at 10:11 AM
Lilly reportedly ready with €15B bid for Abivax firstwordpharma.com/story/7058047
Abivax, balzo in Borsa su indiscrezioni di Opa da parte di Eli Lilly
Il titolo ha visto un balzo fino al +31% sull’ipotesi di un’offerta del gruppo statuni...
https://www.ilsole24ore.com/art/abivax-balzo-borsa-indiscrezioni-opa-parte-eli-lilly-AIfduSp
Il titolo ha visto un balzo fino al +31% sull’ipotesi di un’offerta del gruppo statuni...
https://www.ilsole24ore.com/art/abivax-balzo-borsa-indiscrezioni-opa-parte-eli-lilly-AIfduSp
January 12, 2026 at 10:11 AM
Abivax, balzo in Borsa su indiscrezioni di Opa da parte di Eli Lilly
Il titolo ha visto un balzo fino al +31% sull’ipotesi di un’offerta del gruppo statuni...
https://www.ilsole24ore.com/art/abivax-balzo-borsa-indiscrezioni-opa-parte-eli-lilly-AIfduSp
Il titolo ha visto un balzo fino al +31% sull’ipotesi di un’offerta del gruppo statuni...
https://www.ilsole24ore.com/art/abivax-balzo-borsa-indiscrezioni-opa-parte-eli-lilly-AIfduSp
Abivax shares soar 23% as media report reignites M&A chatter reut.rs/4sBIWlu
Abivax shares soar 23% as media report reignites M&A chatter
Shares in Abivax soared 23%, exceeding 121 euros, on Monday after a media report said U.S. pharma giant Eli Lilly was still interested in buying the French biotech company.
reut.rs
January 12, 2026 at 9:45 AM
Abivax shares soar 23% as media report reignites M&A chatter reut.rs/4sBIWlu
ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
January 12, 2026 at 8:14 AM
ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
January 12, 2026 at 8:13 AM
ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
*ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
January 12, 2026 at 8:13 AM
*ABIVAX SHARES RISE AS MUCH AS 27% IN PARIS TRADING
Bien que n'ayant pas encore soumis d'offre formelle au board d' #Abivax, #Eli_Lilly est toujours dans la course au rachat. Avant de se positionner, le groupe américain attend un signe de Bercy pour savoir si ce rachat serait soumis aux procédures de contrôle des investissements étrangers en France.
⚡️ Eli Lilly prêt à mettre 15 milliards d'euros sur la table pour la biotech #Abivax
www.lalettre.fr/fr/entrepris...
www.lalettre.fr/fr/entrepris...
January 12, 2026 at 6:30 AM
Bien que n'ayant pas encore soumis d'offre formelle au board d' #Abivax, #Eli_Lilly est toujours dans la course au rachat. Avant de se positionner, le groupe américain attend un signe de Bercy pour savoir si ce rachat serait soumis aux procédures de contrôle des investissements étrangers en France.
⚡️ Eli Lilly prêt à mettre 15 milliards d'euros sur la table pour la biotech #Abivax
www.lalettre.fr/fr/entrepris...
www.lalettre.fr/fr/entrepris...
January 12, 2026 at 6:10 AM
⚡️ Eli Lilly prêt à mettre 15 milliards d'euros sur la table pour la biotech #Abivax
www.lalettre.fr/fr/entrepris...
www.lalettre.fr/fr/entrepris...
💹 V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
🔗↗️
https://www.seznamzpravy.cz/clanek/295909 […]
🔗↗️
https://www.seznamzpravy.cz/clanek/295909 […]
Original post on zpravobot.news
zpravobot.news
January 12, 2026 at 5:08 AM
💹 V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
🔗↗️
https://www.seznamzpravy.cz/clanek/295909 […]
🔗↗️
https://www.seznamzpravy.cz/clanek/295909 […]
Vítězové a poražení burzovního světa: Zářil SanDisk, propadla se Puma
V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
Vítězové a poražení burzovního světa: Zářil SanDisk, propadla se Puma - Seznam Zprávy
V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportov...
www.seznamzpravy.cz
January 12, 2026 at 4:49 AM
Vítězové a poražení burzovního světa: Zářil SanDisk, propadla se Puma
V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
V minulém roce sice přinesly největší zisky akcie výrobců pamětí, ale vítězem je francouzská biotechnologická firma Abivax. Naopak investory zklamaly společnosti z oblasti marketingu a výrobci sportovního oblečení a bot.
Εκτόξευση 1.681% πέρυσι για τη μετοχή της Abivax
Εκτόξευση 1.681% πέρυσι για τη μετοχή της Abivax
Η γαλλική εταιρεία βιοτεχνολογίας έδωσε τις καλύτερες αποδόσεις ανάμεσα στα blue chips της Ευρώπης.
www.kathimerini.gr
January 10, 2026 at 12:53 PM
Εκτόξευση 1.681% πέρυσι για τη μετοχή της Abivax
Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine.
🔗Read more: cnb.cx/49ywR85
🔗Read more: cnb.cx/49ywR85
January 9, 2026 at 3:00 PM
Abivax stock rallied in 2025, far outpacing peers, as the French biotech surprised investors with a stellar data readout in July for its lead asset – an ulcerative colitis medicine.
🔗Read more: cnb.cx/49ywR85
🔗Read more: cnb.cx/49ywR85